Metabolic Syndrome and Risk of In-Stent Restenosis: Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention.
10.4070/kcj.2007.37.11.567
- Author:
Jae Kyung HA
1
;
Dong Cheul HAN
;
Ki Won HWANG
;
Dong Won LEE
;
Yung Kwon YUN
;
Han Cheol LEE
;
Jun KIM
;
June Hong KIM
;
Kook Jin CHUN
;
Taek Jong HONG
;
Yung Woo SHIN
Author Information
1. Division of Cardiology, Department of Internal Medicine, College of Medicine, Pusan National University, Busan, Korea. glaraone@hanmail.net
- Publication Type:Original Article
- Keywords:
Metabolic syndrome;
Coronary restenosis;
Stent
- MeSH:
Body Mass Index;
Coronary Restenosis;
Drug-Eluting Stents;
Follow-Up Studies;
Humans;
Hypertension;
Lipoproteins;
Percutaneous Coronary Intervention*;
Retrospective Studies;
Risk Factors;
Stents;
Triglycerides
- From:Korean Circulation Journal
2007;37(11):567-573
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND AND OBJECTIVES: Patients with metabolic syndrome (MS) have an increased risk of cardiovascular events. However, only limited studies are available on the effect of MS on restenosis and on the clinical outcome of patients undergoing percutaneous coronary intervention (PCI). The aim of this study is to assess the role of MS in the development of restenosis, and risk of a 6-month major adverse cardiac event (MACE) and a 12-month MACE, as well as the difference of outcome between the use of bare metal stents (BMSs) and the use of drug eluting stents (DESs). SUBJECTS AND METHODS: This is a one center, retrospective study. The study population comprised 151 patients undergoing percutaneous coronary intervention (PCI) with BMSs and 200 patients undergoing PCI with DESs. The study population was classified into two groups of patients with MS and patients without MS. RESULTS: The baseline clinical characteristics were similar in the two groups (with or without MS) except for hypertension, diabetes, body mass index, triglyceride level and high-density lipoprotein level. The frequency of in-stent restenosis of the patients that were implanted with BMSs or DESs was not different between two groups, based on a 6 month follow-up quantitative coronary angiographic analysis (BMSs: 30% vs 22.2%, p= 0.352; DES: 3.3% vs 2.2%, p=0.76; for patients with and without MS, respectively). The percent of patients with a 6-month MACE for patients implanted with BMSs was not statistically different for patients with or without MS (30% vs 22.2%, p=0.352) but the percent of patients with a 12-month MACE showed a statistically significant higher level for the MS group (38.6% vs 23.5%, p=0.044). The percent of patients with a 6-month MACE for patients implanted with DESs was also not statistically different between two groups (5.8% vs 1.7%, p= 0.123). CONCLUSION: Patients with MS undergoing BMSs or DESs implantation do not show higher levels of in-stent restenosis and levels of a 6-month MACE. The number of 12-month MACEs of patients implanted with BMSs is statistically higher, but the number of 6-month MACEs of patients implanted with DESs is not different for the MS group. We conclude that MS is not risk factor of in-stent restenosis in PCI but MS may influence the long-term clinical outcome in patients undergoing PCI.
